secwatch.observer — SEC 8-K summary
======================================

Issuer:     PROKIDNEY CORP. (PROK)
CIK:        0001850270
Form:       8-K
Filed at:   2025-07-15T23:59:59+00:00
Accession:  0001193125-25-159041
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ProKidney gains FDA alignment on accelerated approval pathway for rilparencel; topline data Q2 2027
--------------------------------------------------------------------------------

- FDA confirmed eGFR slope as surrogate endpoint for accelerated approval of rilparencel in CKD with type 2 diabetes.
- Effect size of at least 1.5 mL/min/1.73m2/year required versus sham; nearly half of required patients enrolled.
- Phase 3 PROACT 1 can serve as both the accelerated and confirmatory study; confirmatory readout timing in 1H 2026.
- Topline data for accelerated approval BLA submission anticipated in Q2 2027.
- Rilparencel holds RMAT designation; CEO called it a critical regulatory milestone.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1850270/000119312525159041/0001193125-25-159041-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1850270/000119312525159041/d477465d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-159041

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer